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Background: Both diabetic and non-diabetic end stage renal disease (ESRD) are more common among Canadian
First Nations people than among the general Canadian population. The purpose of this research was to determine
the prevalence of and risk factors for albuminuria in a Canadian First Nation population at high risk for ESRD and
dialysis.
Methods: Data from a community-based screening study of 483 residents of a Plains Ojibway First Nation in
Manitoba was used. Participants provided random urine samples. Proteinuria was defined as any dipstick positive for
protein (≥1 g/L) or those with ACR in the macroalbuminuric range (≥30 mg/mmol) on at least one sample.
Microalbuminuria was defined as ACR ≥2 mg/mmol for males and ≥2.8 mg/mmol for females. Other measures
included fasting glucose, haemoglobin A1c, triglycerides, cholesterol, blood pressure, height, weight and waist and
hip circumferences.
Results: Twenty percent of study participants had albuminuria, (5% proteinuria and 15% microalbuminuria). Of
participants with diabetes, 42% (56/132) had albuminuria compared to 26% (7/27) among those with impaired
fasting glucose and 10% (30/303) among those with normal glucose tolerance. Only 5.3% of those with albuminuria
were aware of any degree of renal disease. In a multivariate logistic regression, independent associations with
albuminuria were male gender [p = 0.002], increasing fasting glucose [p <0.0001], years diagnosed with diabetes
[p = 0.03], increasing systolic blood pressure [p = 0.009], and increasing body mass index (BMI) [p = 0.04].
Conclusions: The independent association between BMI and albuminuria has not been previously reported among
indigenous populations. There is a high prevalence of albuminuria in this Canadian First Nation population; the high
proportion of patients with diabetes and undiagnosed kidney disease demonstrates the need for screening,
education and intervention to halt the progression and development of albuminuria and ultimately ESRD and CVD.
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The incidence of end-stage renal disease (ESRD) among
Canadian First Nations people is 2.5-4 times greater than
among the non-First Nations population [1-3] and the most
common cause is diabetic nephropathy. The earliest indica-
tor of diabetic renal disease is microalbuminuria [4-10],* Correspondence: jzacharias@exchange.hsc.mb.ca; brucesg@cc.umanitoba.ca
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reproduction in any medium, provided the orwhich appears 5-10 years prior to the onset of overt pro-
teinuria. Proteinuria is a sign of more advanced renal dis-
ease and is a precursor to renal failure [11]. Importantly,
albuminuria is a strong and independent predictor of car-
diovascular and all cause mortality [12]. Additionally, the
impact of renal disease on health care costs and quality of
life for patients and their caregivers is substantial [13-16].
Blood pressure and glucose control among those with
diabetes and/or chronic kidney disease, with either
medication and/or lifestyle changes have shown to be ef-
fective in preventing progression to advanced renal dis-
ease [17-19]. Therefore screening for albuminuria inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fective community-based renal disease prevention
strategy.
While the excess burden of diabetes among First
Nations populations compared to the general Canadian
population is well established [20], research on diabetes-
related kidney disease among Canadian First Nations
populations is more limited. A retrospective population-
based study from Saskatchewan for the years 1981-90
revealed that among those with diabetes, the rate of
ESRD in First Nation people was 7 times greater than
among non-First Nation people [2]. The prevalence of
microalbuminuria among a sample of 601 First Nation
residents in northern Saskatchewan was 24% among
those with diabetes, and 9% among those without [21].
Non-diabetic diseases, such as glomerulonephritis, that
can lead to ESRD and which can present with albumin-
uria and hematuria are also significantly increased in
First Nation people [3]. According to the Canadian Dia-
betes Association Clinical Practice Guidelines, First
Nations adults with at least one risk factor should be
screened for diabetes every 1-2 years and those with type
2 diabetes should be screened for albuminuria at diagno-
sis and annually thereafter [22]. Despite these recom-
mendations and the increased burden of diabetic and
non-diabetic renal disease, few population-based screen-
ing studies for albuminuria among Canadian First Nation
populations have been performed. The study community
reported in this article has a high prevalence of ESRD
(5%), diabetes (29%) and impaired fasting glucose (7%)
[23]. Thus, the community is at high risk for diabetic
renal complications. Therefore the purpose of this paper
is to determine the prevalence and determinants of albu-
minuria in a Canadian First Nation population, and to
begin planning for secondary prevention strategies.
Methods
The data for this paper are from a previously described lar-
ger screening study for diabetes and diabetes complica-
tions [23] conducted in 2003 among adult members of the
Sandy Bay First Nation, located about 200 km northwest
of Winnipeg, Manitoba, Canada, with year round road ac-
cess. Its population in December 2001 was 2,968, of which
52% were under the age of 18. Inclusion criteria were:
non-pregnant, community member, and 18 years and
older. A total of 483 community members participated;
36% of all eligible adults (n= 1356). That is, there were
1356 eligible adults in the community, according to the in-
clusion criteria, and 483 chose to participate. Estimates of
albuminuria were obtained on the 468 participants who
had completed all components of the study, which
included anthropometrics (height, weight, and waist and
hip circumferences); a demographic and health status
questionnaire; fasting blood samples for glucose, A1c,andlipids; and random urine sample. Although albuminuria is
not the best clinical tool to identify kidney disease, for an
epidemiological screening study, albuminuria is an excel-
lent predictor for ESRD, CVD, and all-cause mortality
[12]. This study was approved by the Health Research
Ethics Board at the University of Manitoba.
Measures
Urine albumin:creatinine ratio (ACR) was determined
using the BayerW DCA 2000™ Point-of-Care Analyzer,
which is highly accurate and reproducible [24,25]. Each
urine sample was first tested by a Multistix Reagent
strips for presence of protein, and blood. Participants’
whose samples tested “trace or more” for blood or≥ 1 g/L
protein were requested to return on another day. Sam-
ples negative for blood and protein were loaded into the
DCA 2000™. Microalbuminuria was defined as no posi-
tive dipstick reading for protein and at least one test with
ACR >2.8 mg/mmol for women and >2.0 mg/mmol for
men. Individuals with dipstick positive proteinuria
(>1 g/L) or those with ACR in the macroalbuminuria of
proteinuria range (≥30 mg/mmol) on at least one sample
were considered to have proteinuria. A maximum of
three samples were obtained.
Venous samples for glucose, were drawn after an
overnight 12-hour fast. Participants with fasting glu-
cose values ≥5.8 mmol/L were requested to return for a
second sample; the average of the two samples was
used in analysis. Diabetes was defined as a fasting
blood glucose ≥7.0 mmol/L. Impaired fasting glucose
was defined as fasting blood glucose of 6.1-6.9 mmol/L,
as per the Canadian Diabetes Association [26]. Samples
were analyzed at the Clinical Chemistry Lab at the
Health Sciences Centre, Winnipeg, Manitoba.
Blood pressure was measured on site by a registered
nurse or a trained research assistant, working under the
supervision of the registered nurse. The average of two
readings was used. Hypertension was defined as a blood
pressure >140/90 mm Hg for those without diabetes, ≥130/
80 mm Hg for those with diabetes and/or albuminuria,
according to the American Diabetes Association [27,28], or
a previous diagnosis treated with medication. Anthropomet-
ric measures including height, weight, and waist and hip cir-
cumferences were completed using standard techniques
[29]. Current and past smoking status and number of
cigarettes smoked per day were determined using a stan-
dardized questionnaire. Pack years was calculated as num-
ber of packs per day (1 pack= 20 cigarettes) multiplied by
number of years smoked. Standard demographic informa-
tion and diabetes history were derived via questionnaire.
Awareness of disease states by participant, such as dia-
betes, hypertension and kidney disease, was asked by a
simple direct question in similar fashion to the NHANES
III study cohort [30].
Table 1 Demographic and health risk characteristics of
the study sample
Characteristic Value1
Age (years) 38 (12)a
Female 253 (52)
Grade 9 or higher 220 (47)
Employed 137 (29)
Ever smoked 391 (82)
Current smoker 349 (74)
Hypertension2 201 (43)
Body Mass Index (kg/m2) 31.5 (7)a
Diabetes3 140 (29)
Impaired fasting glucose4 30 (6.2)
Average fasting blood glucose (mmol/L) 5.4 (3.4, 20.6)b
Albuminuria5 95 (20)
Aware6 of diabetes 107(76)
Aware of hypertension 127(63)
Aware of kidney disease 5(5)
1Data are reported as n (percentage), mean (standard deviation)a or median
(range)b.
2Hypertension is defined as a blood pressure >140/90 mm Hg for those
without diabetes, ≥130/80 mm Hg for those with diabetes, or a previous
diagnosis with medications.
3Diabetes is defined as fasting glucose ≥7.0 mmol/L or previous diagnosis.
4Impaired fasting glucose is fasting glucose between 6.1 mmol/L and
6.9 mmol/L with no previous diagnosis of diabetes.
5Albuminuria is albumin:creatinine ratio >2.8 mg/mmol for women and >2.0 mg/
mmol for men.
6Awareness of disease states refers to participant awareness.
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Data are presented as mean (standard deviation) for con-
tinuous variables, median (range) for continuous variables
that do not follow a normal distribution, and as n (percent)
for categorical variables. Demographic, anthropometric and
health characteristics were compared using t-tests for nor-
mally distributed continuous variables, χ2 tests for categor-
ical variables and Mann–Whitney U non-parametric tests
for non-normally distributed continuous variables. Univari-
ate and multiple logistic regression (backwards stepwise)
were used to determine associations with albuminuria.
Continuous variables were also explored as categorical vari-
ables to determine appropriateness of assumptions of lin-
earity. Those variables that were found to be significant in
univariate analysis, as well as independent of age, were
included as potential variables in the backwards step-
wise logistic regression model. Tests were two-tailed
with p< 0.05 considered significant. Statistical analyses
were performed using SPSS (version 16).
Results
The study sample was representative of the larger com-
munity for age, sex, education and employment status
[23]. That is, the sample had similar proportions of the
previously listed characteristics as the study population.
Nine subjects were ineligible due to incomplete data and
6 were excluded from the albuminuria analysis due to
persistent hematuria, leaving 468 subjects for albumin-
uria analysis. Participants with persistent hematuria were
excluded due to the inability to obtain an ACR and we
could not determine the cause of the hematuria. These
individuals were referred for clinical evaluation. How-
ever, most individuals whose first test was positive for
hematuria were found not to be hematuric on subse-
quent tests and were included in analysis. The majority
of these participants were women who were tested close
to their menstrual period.
Demographic and health risk characteristics of the
study population are described in Table 1. Both sexes
were equally represented. The population was young and
the mean age was similar for men and women (37 for
men; 38 for women). Less than half the study sample
had completed grade 9. The study population had high
rates of cardiovascular risk factors; three-quarters of par-
ticipants were current smokers, 43% had hypertension,
35% had diabetes or prediabetes and obesity was highly
prevalent.
Twenty-five percent of the sample returned for at least
a second random urine test (Table 2). However, of those
who had abnormal samples (ie. hematuria or proteinuria)
on their first test, 79% returned for a second or third
test. Albuminuria was present in 95/468 or 20% of parti-
cipants. Twenty-five participants (5%) had proteinuria
and 70 (15%) had microalbuminuria. In univariateanalysis [OR (95% CI) p-value], age [1.039 (1.008, 1.072)
p = 0.014], diabetes [11.474 (4.209, 31.279) p< 0.001],
systolic blood pressure [1.039 (1.019, 1.061) p< 0.001],
diastolic blood pressure [1.051 (1.018, 1.086) p = 0.002],
fasting glucose [1.257 (1.155, 1.367) p< 0.001] and
hypertension [4.390 (1.709, 11.277) p = 0.002] were asso-
ciated with proteinuria. There was a non-significant
trend for lower odds of proteinuria among females
[0.428 (0.181, 1.012) p = 0.053]. BMI, ever smoker, and
years diagnosed with diabetes were not associated with
proteinuria. For all other analysis, those with proteinuria
and microalbuminuria were combined for analysis due to
small numbers and equivalence on the following charac-
teristics: age, sex, smoking status and mean years
smoked. However, the proportion of those with diabetes
was greater among the proteinuria group compared to
the microalbuminuria group. Eighty percent (20/25) of
those with proteinuria had diabetes.
Participants with and without albuminuria are compared
in Table 3. Those with albuminuria were older (p< 0.001)
and albuminuria prevalence progressively increased with
age (Figure 1). Men were more likely to have albuminuria
than women (p=0.01). Interestingly, those with




Normo-albuminuria Microalbuminuriaa Proteinuriab Totals
1 321 (69%) 22 (4.7%) 6 (1.3%) 349 (75%)
2 48 (10%) 39 (8.2%) 14 (3%) 101 (22%)
3 4 (0.8%) 9 (1.9%) 5 (1.1%) 18 (3.8%)
Totals 373 (80%) 70 (15%) 25 (5.3%) 468
aMicroalbuminuria was defined as no positive dipstick reading for protein and at least one test with ACR >2.8 mg/mmol for women and >2.0 mg/mmol for men.
bIndividuals with dipstick positive proteinuria (>1 g/L) or those with ACR in the macroalbuminuria of proteinuria range (≥30 mg/mmol) on at least one sample
were considered to have proteinuria.
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(p= 0.007). However, neither years of smoking nor pack-
years smoked were significantly different between groups.
Participants with albuminuria were more likely to be
hypertensive by any measure. Seventy percent (70%) of
those with albuminuria had hypertension compared with







Age (years) 42 (13) 36 (12) <0.001
Sex
Female 38 (40.4) 201 (54.0) 0.02
Male 56 (59.6) 171 (46.0)
Ever a smoker 67 (72.0) 311 (84.1) 0.007
Years smokeda 12 (0,50) 10 (0,50) 0.941
Pack years smokeda 1.5 (0,88) 2.6 (0,74) 0.291
Previous hypertension
diagnosis
38 (42.7) 78 (21.9) <0.001
Hypertension1 64 (68.8) 131 (35.7) <0.001
Systolic BP (mm Hg)b 134 (19) 125 (15) <0.001
Diastolic BP (mm Hg)b 80 (12) 76 (10) <0.001
Blood pressure ≥130/
80 mm Hg2
62 (66.0) 189 (51.2) 0.01
Body Mass Index
(kg/m2)b
32.9 (5.79) 31.1 (7.25) 0.03
Diabetes3 57 (60.6) 77 (20.7) <0.001
Dysglycemia4 64 (68.1) 97 (26.1) <0.001
Fasting glucose
(mmol/L)b
9.7 (4.6) 6.2 (2.6) <0.001
Hematuria5 8.4 2.9 0.001
Data are reported as n (percentage), mean (standard deviation)a, median
(range)b.
1Hypertension is defined as a previous diagnosis of hypertension or blood
pressure ≥140/90 mm Hg.
2Blood pressure ≥130/80 mm Hg includes only participants with previous
diagnosis of diabetes or hypertension.
3Diabetes is defined as on oral hypoglycemics, self declared diabetes or has a
fasting glucose ≥7.0 mmol/L.
4Dysglycemia is defined as previous diagnosis of diabetes or a fasting plasma
glucose ≥6.1 mmol/L.
5Hematuria was a positive dipstick for hemoglobin.regard, mean blood pressures were significantly higher in
the group with albuminuria compared to those without.
Target blood pressure in those with albuminuria is gener-
ally recommended to be <130/80 mm Hg, however, this
was achieved in only 34% of those with albuminuria.
Participants with albuminuria were significantly heav-
ier and had a higher BMI (Figure 2). This increased
weight and BMI may be related to the greater proportion
of participants in the albuminuric group with diabetes
and impaired fasting glucose. Fasting glucose was also
higher among those with albuminuria compared to those
without (p< 0.001). While almost 60% of those with any
degree of albuminuria had diabetes, 42% of those with
diabetes were albuminuric.
Odds ratios and 95% CI are listed in Table 4 for both
univariate and multivariate logistic regression. Backwards
stepwise multivariate logistic regression was performed.
Univariate analysis indicated the odds of having microal-
buminuria increased 4% for each year increase in age.
However, age was not significant in the final multivariate
model. When both fasting glucose and years of diabetes
were removed from the model and age was included, age
became significant suggesting high multicolinearity be-
tween the diabetes and age (model not shown). Females
were less likely to have microalbuminuria than males,
which remained significant in the multivariate model.
Smokers were less likely to have albuminuria than non-
smokers and while smoking appeared protective in uni-
variate analysis, it did not achieve significance in the
multivariate model.
Those with diabetes were seven times more likely to
have albuminuria than those without diabetes. In
addition, for each mmol/L increase in average fasting
glucose, albuminuria increased by 27% in the univariate
model, and 20% when controlling for sex, years diag-
nosed with diabetes, systolic blood pressure and BMI.
Length of time with diabetes was also a significant pre-
dictor of albuminuria and confirms the natural history of
diabetic nephropathy. Systolic blood pressure was inde-
pendently associated with albuminuria in the multivari-
ate model and risk of albuminuria increased by 2% for
every mm Hg increase in systolic blood pressure. Lastly,
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Figure 1 Percent albuminuria by age categories. There is a significant linear association between age group and proportion of those with
albuminuria (p< 0.001). ‘n’ refers to the total number of participants in respective age category.
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variate analysis, after accounting for average fasting glu-
cose, gender, years diagnosed with diabetes mellitus and
systolic blood pressure [1.042 (1.001, 1.085), p = 0.04].
In contrast to participants with diabetes and hyperten-
sion, very few with albuminuria were aware of their condi-
tion. Participant awareness of kidney disease increased
with severity such that 17% of those with proteinuria were
aware of kidney disease while awareness kidney disease in
those with microalbuminuria was only 1% (Table 1).
Discussion
High prevalence of diabetes and renal complications of
diabetes (ESRD) have been previously described among
Canadian First Nations people [1,2,31-33]. Significant rates
of renal complications (ESRD) among non-diabetic First
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Figure 2 Percent albuminuria by BMI categories. There is a significant l
albuminuria (p< 0.001). ‘n’ refers to the total number of participants in respwell recognized as a significant precursor to either diabetic
or non-diabetic renal disease, and has been described in
both those with and without diabetes. In the current popu-
lation-based study, albuminuria rates of 20% among the
total population were as high as among other high-risk
populations such as the Pima in the southwestern United
States [4,7,35]. Among those with diabetes in our study,
42% had albuminuria, which is substantially greater than
the prevalence among the general US population (28.8%)
as described in the NHANES III study [36], and the 24%
estimated in a Canadian First Nation population-based
study in Saskatchewan [21]. The present study prevalence
is comparable to the American Pima and Zuni populations
in which 47% and 52% of the diabetic population, respect-
ively, had albuminuria [7,15].
The current study found female gender protective for





inear association between BMI category and proportion of those with
ective age category.
Table 4 Univariate and multivariate logistic regression
with albuminuria as an outcome
Odds ratio (95%CI) p-value
Univariate logistic regression
Age, years 1.040 (1.021,1.059) <0.0001
Sex
Male 1
Female 0.560 (0.354, 0.885) 0.01
Ever smoked
No 1
Yes 0.485 (0.285,0.825) 0.01
Diabetes mellitus
No 1
Yes 7.718 (4.412, 13.5) <0.001
Average fasting glucose, mmol/L 1.27 (1.192, 1.352) <0.001
Years diagnosed with DM 1.127 (1.078, 1.179) <0.001
Hypertension
No 1
Yes 2.860 (1.790, 4.560) <0.001
Systolic blood pressure, mmHg 1.032 (1.019, 1.046) <0.001
Diastolic blood pressure, mmHg 1.034 (1.013, 1.055) <0.005
BMI 1.036 (1.004, 1.070) 0.03
Hematuria
No 1




Female 0.407 (0.230, 0.771) 0.002
Average fasting glucose, mmol/L 1.200 (1.115, 1.29) <0.001
Years diagnosed with DM 1.057 (1.004, 1.113) 0.03
Systolic blood pressure, mmHg 1.020 (1.005, 1.035) 0.01
BMI 1.042 (1.001, 1.085) 0.04
DM, diabetes mellitus; BMI, body mass index.
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was also found in the Strong Heart Study [37]. This con-
trasts with the NHANES III and Pima Indian non-dia-
betic data, in which women had significantly more
albuminuria than men [7,36]. The NHANES III study,
however, did not use the lower cut-off for ACR in males,
as did the current study. A different ACR cut-off due to
higher excreted creatinine in males has been supported
by many investigators and is supported by the Canadian
Diabetes Association Clinical Practice Guidelines [26,38-
40], and may account for the differences between the
NHANES and Pima Indian non-diabetic data and the
current study. Furthermore, in the Pima diabetic popula-
tion and the Zuni Indian population studies, no sexdifferences were seen [4,7,35]. Mortality rates among
men with albuminuria tend to be higher than in women
[41], and therefore the increased albuminuria among
men in our study is concerning.
BMI was also independently related to increased
prevalence of albuminuria in the study sample. Although
increased BMI has been described as a risk factor for al-
buminuria and proteinuria [42] and high BMI is an issue
among those of First Nations ancestry [43-45], to our
knowledge, BMI has not been previously described as an
independent risk factor for microalbuminuria in the
Canadian First Nations population.
While age has been found to be significantly associated
with albuminuria [36], age was not included in our final
multivariate model, likely due to high multicolinearity
with duration of diabetes and diabetes itself. However,
the average age of those with albuminuria increased by
glycemic status (i.e., non-diabetes, IFG and diabetes).
While by no means confirmatory, this suggests a possible
difference in lead time. As albuminuria is a risk factor
for diabetes [46], those younger individuals with dysgly-
cemia and even without diabetes, may develop diabetes
as they age.
Participant awareness of kidney disease in a First Nation
community is reported here for the first time. Awareness
of kidney disease within the study population was low
compared to other disease states such as diabetes and
hypertension. Awareness of kidney disease was also lower
than that found among the general U.S. population where
24% of participants reported being aware of their kidney
disease [29]. Disease awareness is related to many factors
at both the individual and systems levels. At the individual
level, reported awareness of disease can be limited by pa-
tient understanding and denial; that is, although care pro-
viders may inform patients of their illness, patients may
not integrate that information. Another factor affecting
awareness is lack of screening or diagnostic testing on the
part of health care providers, thereby preventing detection.
At the systems level, access to physicians on the part of
patients and suitable practice environments for physicians
(i.e., access to and remuneration for diagnostic testing) can
either enable or act as barriers to preventive practice. Fac-
tors influencing poor disease awareness among our study
population could not be determined. Thus, further re-
search is required to address the lower than anticipated
awareness in this high-risk population.
The study is subject to limitations. The sample size is
limited and was not randomly selected from the eligible
population. However, our sample was representative of the
eligible study population on demographic factors (i.e., age,
sex, employment, education) and, as previously reported
[23], was not over-represented by the ill or infirmed. In
fact, only 38% of those known to have diabetes at the start
of the study were participants. In addition, only three out
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the study, and none of the 15 individuals with ESRD parti-
cipated. Therefore, we are confident that our sample
represents the larger community. However, the results
may not be generalizable beyond the study population be-
cause we are not able to determine if the study population
is representative of First Nations communities across
Canada. Furthermore, the lack of availability of serum cre-
atinine to further indicate severity of renal dysfunction is
also a limitation. Lastly, those participants that had a nor-
mal ACR did not complete repeat testing.
Conclusions
Albuminuria is an important complication of diabetes and
a risk factor for ESRD and cardiovascular disease. Identifi-
cation of relevant risk factors is therefore an important ac-
tivity that can assist in the development of targeted
prevention efforts. Interestingly, we found the presence of
significant numbers of people with microalbuminuria and
hematuria without other risk factors, confirming the pres-
ence of non-diabetic renal disease. Further investigations
should be focused on this group; first to help ascertain the
cause of their hematuria or albuminuria, and second to
intervene appropriately. Lack of awareness of early renal
disease among study participants is a concern and efforts
to understand the phenomenon and improve awareness
will be undertaken in partnership with the community.
Ongoing longitudinal follow-up of the individuals in this
study would further our understanding of the significance
of individual health determinants. In addition, further
follow-up would give important information about the
natural history of albuminuria in this population. The
response to treatment and community intervention strat-
egies could also be assessed.
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